GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Cyclically Adjusted PS Ratio

Avalo Therapeutics (STU:C6K0) Cyclically Adjusted PS Ratio : (As of Jun. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Avalo Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Cyclically Adjusted PS Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.01 0.01

Avalo Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 0.01 -

Competitive Comparison of Avalo Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Avalo Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avalo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Avalo Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/134.9266*134.9266
=0.000

Current CPI (Mar. 2025) = 134.9266.

Avalo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 193.000 101.688 256.085
201609 95.333 101.861 126.280
201612 57.333 101.863 75.943
201703 89.750 102.862 117.727
201706 28.200 103.349 36.816
201709 1,750.583 104.136 2,268.199
201712 171.636 104.011 222.652
201803 330.545 105.290 423.587
201806 372.364 106.317 472.567
201809 291.000 106.507 368.649
201812 -396.429 105.998 -504.621
201903 152.000 107.251 191.224
201906 82.133 108.070 102.544
201909 133.267 108.329 165.987
201912 34.867 108.420 43.391
202003 131.158 108.902 162.502
202006 54.000 108.767 66.987
202009 36.269 109.815 44.563
202012 47.346 109.897 58.129
202103 12.806 111.754 15.461
202106 84.394 114.631 99.336
202109 32.800 115.734 38.239
202112 4.217 117.630 4.837
202203 27.308 121.301 30.375
202206 25.051 125.017 27.037
202209 387.128 125.227 417.115
202212 21.692 125.222 23.373
202303 9.061 127.348 9.600
202306 10.224 128.729 10.716
202309 1.133 129.860 1.177
202312 0.653 129.419 0.681
202403 0.000 131.776 0.000
202406 0.000 132.554 0.000
202409 0.021 133.029 0.021
202412 0.017 133.157 0.017
202503 0.000 134.927 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avalo Therapeutics  (STU:C6K0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avalo Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Headlines

No Headlines